Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

InterVene gets $15mm from Series B financing

Executive Summary

InterVene Inc. raised $15mm via a Series B financing led by 3×5 Partners, which was joined by returning shareholders including RiverVest Venture Partners, Boston Scientific, and Correlation Ventures. The company will use the proceeds for clinical trials of its BlueLeaf endovenous valve formation system, which is the first catheter-based device for deep vein reflux that does not require an implant.
Deal Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies